Protective Effect of Valsartan on Beleomycine-Induced Fibrosis
| Author | Hoda Mojiri Forushani | en |
| Author | Ali Asghar Hemmati | en |
| Author | Ali Khodadadi | en |
| Author | Mohammad-Ali Assarehzadegan | en |
| Author | Mohammad Rashno | en |
| Issued Date | 2017-02-28 | en |
| Abstract | Background: Pulmonary fibrosis (PF) is among the world’s most prevalent and common respiratory system diseases. Several previous studies have revealed the contribution of angiotensin in the pathogenesis of PF; subsequently, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor antagonists (ARDs) have been proposed for the treatment of pulmonary fibrosis using therapeutic approaches. Objectives: This study aimed to investigate the anti-fibrotic effect of valsartan as an angiotensin receptor blocker. Methods: Rats were given a single intratracheal administration of bleomycin (7.5 IU/kg); valsartan (20, 40, 80 mg/kg/day) was administrated to the rats orally, starting seven days before the induction of lung fibrosis and continuing until the end of the study. The control group received a vehicle. Results: The rats that received valsartan exhibited decreased hydroxyprolin content and pulmonary index values. Pathological examination showed that valsartan could prevent inflammation and fibrotic scarring induced by bleomycin. Conclusions: Valsartan displayed an anti-fibrotic and protective effect against bleomycin-induced lung fibrosis in an animal model. | en |
| DOI | https://doi.org/10.5812/jjnpp.33973 | en |
| Keyword | Valsartan | en |
| Keyword | Pulmonary Fibrosis | en |
| Keyword | Angiotensin | en |
| Keyword | Bleomycin | en |
| Publisher | Brieflands | en |
| Title | Protective Effect of Valsartan on Beleomycine-Induced Fibrosis | en |
| Type | Research Article | en |